Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre
Authors:
- Antonio De LeoALAntonio De Leo
- Daniela SerbanDSDaniela Serban
- Thais MalobertiThais Maloberti
- Viviana SanzaVSViviana Sanza
- Sara ColuccelliSCSara Coluccelli
- Annalisa AltimariAAAnnalisa Altimari
- Elisa GruppioniEGElisa Gruppioni
- Federico ChiarucciFCFederico Chiarucci
- Angelo Gianluca CorradiniACAngelo Gianluca Corradini
- Andrea RepaciARAndrea Repaci
- Alessandra ColapintoACAlessandra Colapinto
- Margherita NanniniMNMargherita Nannini
Open Access
- 17 February 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4057
Abstract
The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is potentially related to aggressive behavior and persistent disease. BRAF alterations other than the p.V600E are less common in thyroid carcinoma and represent an alternative mechanism of BRAF activation with unclear clinical significance. The study aims to describe the frequency and clinicopathologic characteristics of BRAF non-V600E mutations in a large cohort (1654 samples) of thyroid lesions characterized by next-generation sequencing. BRAF mutations have been found in 20.3% (337/1654) of thyroid nodules, including classic (p.V600E) mutation in 19.2% (317/1654) of samples and non-V600E variants in 1.1% of cases (19/1654). BRAF non-V600E alterations include 5 cases harboring p.K601E, 2 harboring p.V600K substitutions, 2 with a p.K601G variant, and 10 cases with other BRAF non-V600E alterations. BRAF non-V600E mutations have been reported in one case of follicular adenoma, three cases of conventional papillary thyroid carcinoma, eight cases of follicular variant of papillary carcinomas, one case of columnar cell variant papillary thyroid carcinoma, one case of oncocytic follicular carcinoma, and two bone metastasis of follicular thyroid carcinoma. We confirm that BRAF non-V600E mutations are uncommon and typically found in indolent follicular-patterned tumors. Indeed, we show that BRAF non-V600E mutations can be found in tumors with metastatic potential. However, in both aggressive cases, the BRAF mutations were concomitant with other molecular alterations, such as TERT promoter mutation.Keywords
Funding Information
- Italian Ministry of Health (RC-2022-2773478)
This publication has 31 references indexed in Scilit:
- High-SensitivityBRAFMutation Analysis:BRAFV600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2014
- BRAF mutations in thyroid tumors from an ethnically diverse groupHereditary Cancer in Clinical Practice, 2012
- Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomasLaboratory Investigation, 2012
- BRAF K601E Mutation in a Patient with a Follicular Thyroid CarcinomaThyroid®, 2011
- Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressivenessVirchows Archiv, 2005
- Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinomaLaboratory Investigation, 2004
- BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2004
- BRAF mutations are associated with some histological types of papillary thyroid carcinomaThe Journal of Pathology, 2004
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003
- Mutations of the BRAF gene in human cancerNature, 2002